Schonfeld Strategic Advisors’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-7,264	Closed	-$349K	–	1670
2020 Q1	$349K	Buy	+7,264	New	+$338K	0.02%	702
2019 Q3	–	Sell	-184,800	Closed	-$5.56M	–	1346
2019 Q2	$5.56M	Sell	184,800 -29,600	-14%	-$678K	0.2%	127
2019 Q1	$4.8M	Buy	+214,400	New	+$4.61M	0.17%	162

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Schonfeld Strategic Advisors's RARX Position: Q2 2020 in Review

Schonfeld Strategic Advisors sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 7,264 shares — an estimated $349K sold.

Schonfeld Strategic Advisors first reported a position in RARX in Q1 2019 and held it in 3 quarters. The position peaked at $5.56M in Q2 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Schonfeld Strategic Advisors reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Schonfeld Strategic Advisors sold 7,264 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $349K.
Schonfeld Strategic Advisors first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 3 quarters.
Schonfeld Strategic Advisors's Ra Pharmaceuticals, Inc. Common Stock position peaked at $5.56M in Q2 2019.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.